Figure 4.

Effect of CRET and/or sorafenib on EGFR and ERK expression and activation. Western blotting results for p-ERK, ERK, p-EGFR and EGFR expression are presented. The samples were treated with CRET alone (4 h intermittent exposure), sorafenib alone (4 h) or in combination. Data are presented as the ratio of (A) p-ERK1/2 over total ERK1/2 protein and (B) p-EGFR over total EGFR protein. Data are presented as the mean ± SEM of ≥3 experimental replicates. *P<0.05. Data were statistically analyzed using One-way ANOVA followed by Bonferroni post-hoc test. (C) Representative western blots using β-actin as the loading control. CRET, capacitive-resistive electrothermal therapies; p-, phosphorylated; Sorf, sorafenib; C, control.